Compare GE Vernova Inc (GEV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs State Street SPDR S&P Biotech ETF — how do they compare? GE Vernova Inc trades at $1,004.73 (market cap $266.16B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: GE Vernova Inc is far larger — about 26.3× State Street SPDR S&P Biotech ETF's market cap, and GE Vernova Inc pays a 0.2% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GEV | XBI | |
|---|---|---|
Market Cap | $266.16B | $10.11B |
Volume | 2,324,165 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $1.17K | $169.55 |
52-Week Low | $547.96 | $104.99 |
Typical Hold Time | 36 Days | 38 Days |
Enterprise Value | $255.83B | — |
Dividend Yield | 0.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $999.35, up 0.23% with strong bullish technical signals and positive analyst sentiment. The stock shows impressive fundamentals with 91.48% ROE and 23.04% net income margin, though valuation multiples appear elevated with P/E of 28.65 and EV/EBITDA of 85.22. Recent developments include securing the first US construction permit for its BWRX-300 SMR and benefiting from AI-driven power demand growth.
Outlook remains positive with 75.86% analyst buy ratings and $1,270 consensus price target representing 27% upside. Key risks include execution challenges in wind power segment and stretched valuations. The company's $176 billion backlog and AI infrastructure positioning support long-term growth potential despite near-term valuation concerns.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
